NVO vs. AZN

In the year-to-date period, NVO achieves a -26.02% return, which is significantly lower than AZN's 7.64% return. Both investments have delivered pretty close results over the past 10 years, with NVO having a 10.45% annualized return and AZN not far behind at 10.39%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NVO) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NVO Sharpe Ratio is -1.18, which is lower than the AZN Sharpe Ratio of 0.05. The chart below compares the historical Sharpe Ratios of NVO and AZN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

NVO's dividend yield for the trailing twelve months is around 2.58%, more than AZN's 2.20% yield.

The maximum NVO drawdown since its inception was -70.96%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for NVO and AZN. For additional features, visit the drawdowns tool.

Novo Nordisk A/S (NVO) has a higher volatility of 16.91% compared to AstraZeneca PLC (AZN) at 11.25%. This indicates that NVO's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Novo Nordisk A/S and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.